T1	PrimaryOutcome 38 218	difference in the interval from baseline (initiation of antiviral treatment) to SARS-CoV-2 nucleic acid negativity by nasopharyngeal swab among the three antiviral treatment groups
T2	SecondaryOutcome 306 410	differences among the three groups in the proportion of patients with SARS-CoV-2 nucleic acid negativity
T3	SecondaryOutcome 426 440	mortality rate
T4	SecondaryOutcome 456 532	proportion of patients re-classified as severe cases during the study period
T5	SecondaryOutcome 538 589	incidence of adverse events during the study period
T6	SecondaryOutcome 599 687	proportion of therapeutic discontinuations due to adverse events during the study period
T7	TimeFrame 411 420	at day 14
R1	MeasuredAt Arg1:T2 Arg2:T7	
T8	TimeFrame 441 450	at day 28
R2	MeasuredAt Arg1:T3 Arg2:T8	
T9	OutcomeDefinition 729 970	defined as the presence of negative SARS-COV-2 results in at least two consecutive nasopharyngeal swabs by reverse transcriptase polymerase chain reaction (RT-PCR), with an interval of at least 24 h between the two time points of swab-taking
R3	DefinedAs Arg1:T1 Arg2:T9	
